BMRN FY2025 EPS Forecast Increased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings estimates for BioMarin Pharmaceutical (BMRN) from $3.58 to $3.60 per share, which is above the current consensus estimate of $3.15.
• Multiple firms have adjusted their price targets for BioMarin, with JPMorgan Chase increasing its target from $108 to $113, while Citigroup lowered its target from $82 to $78.
• Institutional investors own approximately 98.71% of BioMarin's stock, with notable recent increases in stakes from CIBC Private Wealth Group and Quadrant Capital Group.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of BioMarin Pharmaceutical in a report released on Tuesday, August 5th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biotechnology company will post earnings of $3.60 per share for the year, up from their prior forecast of $3.58. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share.

A number of other research firms have also recently commented on BMRN. Wall Street Zen cut shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Citigroup lowered their price objective on shares of BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Morgan Stanley reduced their target price on shares of BioMarin Pharmaceutical from $97.00 to $96.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 22nd. Guggenheim lifted their price target on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, UBS Group increased their price objective on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a "buy" rating in a research note on Tuesday. Six analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $93.17.

BioMarin Pharmaceutical Trading Down 3.6%

BMRN stock traded down $2.13 during midday trading on Wednesday, reaching $57.33. The company's stock had a trading volume of 3,523,307 shares, compared to its average volume of 2,308,645. BioMarin Pharmaceutical has a 1 year low of $52.93 and a 1 year high of $94.85. The firm has a market capitalization of $11.01 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 0.82 and a beta of 0.18. The stock has a fifty day simple moving average of $57.29 and a two-hundred day simple moving average of $61.74. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.49 and a current ratio of 5.56.

Insider Activity at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 1,786 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer owned 14,173 shares of the company's stock, valued at $840,600.63. This represents a 11.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of large investors have recently made changes to their positions in the business. Nuveen LLC acquired a new position in BioMarin Pharmaceutical during the 1st quarter valued at about $184,475,000. Capital Research Global Investors boosted its holdings in BioMarin Pharmaceutical by 23.8% in the fourth quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company's stock worth $853,944,000 after acquiring an additional 2,496,817 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of BioMarin Pharmaceutical by 127.9% during the first quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company's stock worth $203,987,000 after acquiring an additional 1,642,206 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of BioMarin Pharmaceutical by 212.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company's stock worth $112,607,000 after acquiring an additional 1,083,512 shares during the last quarter. Finally, Soleus Capital Management L.P. acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at about $65,822,000. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.